Plasmin effect on platelet glycoprotein Ib-von Willebrand factor interactions

Area of Science:

• Hematology
• Biochemistry
• Pharmacology

Background:

• Platelet aggregation is crucial for hemostasis.
• Streptokinase and plasmin are thrombolytic agents with potential effects on platelet function.
• Understanding these effects is vital for managing thrombotic disorders and thrombolytic therapy.

Purpose of the Study:

• To investigate the impact of streptokinase on platelet-rich plasma (PRP) and plasmin on washed platelets.
• To elucidate the mechanisms by which these agents affect platelet agglutination and aggregation.
• To identify specific platelet proteins affected by plasmin treatment.

Main Methods:

• Platelet-rich plasma (PRP) and washed platelets were treated with varying concentrations of streptokinase and plasmin.
• Ristocetin-induced platelet agglutination and aggregation induced by ADP, thrombin, and collagen were measured.
• Thrombin time was assessed.
• Sodium dodecyl-polyacrylamide gel electrophoresis (SDS-PAGE) and autoradiography were used to analyze platelet proteins.
• Enzyme-linked immunosorbent assay (ELISA) was employed to detect glycocalicin-related antigen.

Main Results:

• Streptokinase significantly reduced ristocetin-induced platelet agglutination and inhibited aggregation induced by ADP, thrombin, and collagen.
• Streptokinase prolonged thrombin time in PRP.
• Plasmin markedly reduced ristocetin-mediated agglutination of washed platelets in the presence of von Willebrand factor (vWF).
• Plasmin treatment led to the loss of a 180,000 mol wt protein (likely glycoprotein Ib) and the appearance of a 135,000 mol wt protein (glycocalicin) in the surrounding medium.
• Plasmin treatment released glycocalicin-related antigen into the medium, correlating with the loss of vWF-dependent agglutination.

Conclusions:

• Streptokinase and plasmin exert significant inhibitory effects on platelet function.
• Plasmin degrades glycoprotein Ib, leading to the release of glycocalicin and impaired vWF-dependent platelet aggregation.
• These findings highlight the complex interactions between thrombolytic agents and platelet hemostatic mechanisms.